Insider trades
Joel Lewis, CEO of Galectin Therapeutics GALT, has filed 2 purchases and 12 sales on the open market. Over the past 12 months that comes to a net sale of $620.9K. The latest trade was on 01/16.
Joel Lewis
President and CEO
- Company
- Galectin Therapeutics GALT
- First filing
- 23/03/16
- Trades
- 72 trades
- Buys / sales
- 2 / 12
- 12-month net buying
- −$620.9K
- Last trade
- 01/16
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
GALT | Open-market sale10b5-1 plan | 01/02–01/06 | 01/06 | 84,000 sh3 trades | $3.83avg. | $321,385.25 | −9.2% |
| Open-market sale10b5-1 plan | 25/12/17 | 25/12/19 | 7,829 sh | $7.06 | $55,272.74 | −0.9% | |
GALT | Open-market sale10b5-1 plan | 25/11/17–25/11/18 | 25/11/19 | 22,463 sh2 trades | $6.07avg. | $136,422.65 | −2.6% |
| Open-market sale10b5-1 plan | 25/11/10 | 25/11/12 | 1,867 sh | $6.03 | $11,258.01 | −0.2% | |
| Open-market sale10b5-1 plan | 25/11/05 | 25/11/07 | 200 sh | $6.00 | $1,200 | −0.0% | |
GALT | Open-market sale10b5-1 plan | 25/11/03–25/11/04 | 25/11/05 | 15,720 sh2 trades | $6.07avg. | $95,342.4 | −1.9% |
| Open-market sale10b5-1 plan | 25/09/12 | 25/09/15 | 14,000 sh | $6.36 | $89,040 | −1.7% | |
| Open-market sale10b5-1 plan | 24/12/23 | 24/12/26 | 56,000 sh | $0.89 | $49,840 | −5.9% | |
| Open-market buy | 24/04/24 | 24/04/25 | 1,000 sh | $3.39 | $3,390 | +100.0% | |
| Open-market buy | 23/02/16 | 23/02/21 | 1,000 sh | $1.52 | $1,520 | No record |